Cytokinetics, Inc. (NASDAQ:CYTK)

If you are a biotech with cash & you have a decent & devoloping pipeline, you are at least half way to a pot of gold

Following ZZ and hoping to find some support at this price.

The long-term price chart of Cytokinetics is sadly very typical of biotech IPO's. While it seems like the company has been on a roller coaster of alternating catalysts and wild price swings over the last decade, the grim reality is a choppy downward slope to the current sub-1 cesspool. Everyone likes to think of companies like Celgene, Vertex, and Alexion when they plunk their money into baby biotech, but for every Celgene there are twenty Cytokinetics. The odds for coming out ahead in a long-term buy and hold are extremely low.

Cytokinetics' foremost asset is cardiac myosin activator omecantiv, currently being tested in the ATOMIC-AHF phase IIb trial for CHF run by partner Amgen. The trial is proceeding with glacial slowness, having just finished enrolling the initial 200 patient cohort after a year. The companies will decide on progression to a second cohort this quarter after an IDMC review. The second pipeline candidate is skeletal myosin activator CK-2017357, currently generating data in phase II trials in ALS and myasthenia gravis. Recently the company reported trends towards functional improvement in ALS, although they claim the trials weren't powered to show statistical significance. It's hard to foresee any major catalyst from these trials in 2012.

There's always a temptation to buy in at these levels, especially when the company has cash and they're progressing the pipeline. However, I think it's always a good idea to step back and look at the long-term chart to remind yourself that even if there's a positive catalyst or a price rebound, you're fighting a strong downward trend and it's a good idea to keep your finger pretty close to the sell button. I've already been burned in CAPS green-thumbing at a higher level last year, but I'm willing to mark the stub here as it carves out new all-time lows once again.

Bio play

Very specific product that will be promoted at an upcoming 4 conferences over the course of the next 2 months.

Made points in at lower price looking for more

Following tenmiles, I like what I saw when doing my initial research. Will be checking up on it more to see if I'm ready to throw down some real coin on it.

Like the risk/reward at $1.47 for at least a trade

bought today at 1.32...like the entry level and volume here for a potential partnership catalyst and decent cash position.

Bounce play only. Should see 1.70ish IMO.

The bottom I hope.

it will hit @ $ 10.15

I believe the stock has more or less found a bottom. They have a reasonable amount of cash, and an interesting pipeline. I think the stock will be trend up slowly.

Their drug developments and clinical trials are promising. I think they will do better in the future.

This one looks like it could be heaed to the scrap heep....

guru short

if even i of its drugs being tested prove successful, it will be a good thing for terminal patients and investors

Bargain basement. Giving it away at these prices.

CYTK is undervalued by virtue of its pipeline, trials and tech. While many love other groups perceived to be similar such as EXEL, CYTK will excel (sorry) because of a relative lack of promiscuity between the drugs and their targets.